RE:RE:RE:RE:RE:Low Volume + High Share ControlMM-Thanks
maybe damaging was the wrong term. But the SP did decline dramatically after last Fall's FDA DIMI approval. And it did sell off on low volume on this most recent FDA trial news.
I too expect that Dr Kellum's presence will lead to a more credible Valuation for the reasons you have noted.